2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Immunology, Neutropenia, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5305 ­­­Impact of PET functional volumetrics on outcomes in newly diagnosed mantle cell lymphoma

Mohammad Oussama Ali, MD, Fang Yu, PhD2, Yijun Li3, Olivia Makos4, Alexander Schmitz5, Luke Doyle6, James Olen Armitage, MD7, Julie Vose, MD8, Matthew A. Lunning, DO, FACP9, Snegha Ananth, MD10, Christopher D'Angelo, MD, MS11
1 University of Nebraska Medical Center, Omaha, Nebraska, United States
2 University of Nebraska Medical Center, Omaha, Nebraska, United States
3 University of Nebraska Medical Center, Omaha, Nebraska, United States
4 University of Nebraska Medical Center, Omaha, Nebraska, United States
5 University of Nebraska Medical Center, Omaha, Nebraska, United States
6 University of Nebraska Medical Center, Omaha, Nebraska, United States
7 University of Nebraska Medical Center, Omaha, United States
8 University of Nebraska Medical Center, Omaha, Nebraska, United States
9 University of Nebraska Medical Center, Omaha, Nebraska, United States
10 University of Nebraska Medical Center, Omaha, United States
11 University of Nebraska Medical Center, Omaha, Nebraska, United States

Background
Prognosis in mantle cell lymphoma (MCL) is informed by the MIPI score, Ki-67, TP53 status, & histologic subtype. Improving risk stratification in MCL is an unmet need given the clinical & biologic heterogeneity, limitation of existing prognostic tools in guiding therapy, & the evolution of the treatment landscape. PET-derived total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) are prognostic in different lymphoma subtypes, but their independent prognostic value in MCL remains limited. We assessed whether baseline TMTV and TLG predict response and survival in MCL and add discrimination beyond established variables.

Methods
We reviewed 111 adults with newly diagnosed MCL at the University of Nebraska Medical Center from 2010-2024. Baseline PET/CT with TMTV was evaluable in 94 and TLG in 93 patients. TMTV and TLG were obtained from pretreatment 18F-FDG PET/CT using PERCIST criteria (1.5 × mean SUV + 2SD). TMTV and TLG were modeled continuously, and dichotomized by the median, and TMTV was also dichotomized by 2 published MCL thresholds (141 ml, 92.2 ml). Univariate and multivariate logistic regression, and cox-proportional hazard models were used to evaluate effect on complete response (CR), objective response, progression-free survival (PFS), and overall survival (OS) after frontline therapy. All multivariable regression used backward variable selection (p value >0.1 for removal) to identify important covariates to be adjusted after including four key variables: MIPI level, TP53 status, histology, TMTV or TLG.  A composite of MIPI and median-dichotomized TMTV was explored in 3 categories: high TMTV with intermediate/high MIPI, low TMTV with intermediate/high MIPI, and low MIPI.

Results
Median age was 62 years (37-88); 79 (71.2%) patients were male and 98 (88.3%) had stage IV disease. MIPI risk was low, intermediate, and high in n: 36/108 (33.3%), n: 43/108 (39.8%), and n: 29/108 (26.9%), respectively. Ki-67 >30% was present in n: 32/79 (40.5%), LDH was elevated in n:50/108 (46.3%), TP53 was mutated in n: 13/72 (18.1%), n: 17 (15.3%) had blastoid/pleomorphic morphology, and n: 43/100 (43.0%) met GELF criteria. Front-line management consisted of chemoimmunotherapy (n: 86, 77.5%), BTKi-based therapy (n: 21, 18.9%), other therapy (n: 1, 0.9%), and observation without subsequent treatment (n: 3, 2.7%). Autologous stem cell transplantation was performed in n: 48 (43.2%). At a median follow-up of 39.1 months (3.3-185.5), n :41 (36.9%) had died. Median baseline TMTV was 196 mL (0-7614) and median TLG was 589 (0-28620). CR was achieved in 80 (81.6%). Continuous TMTV was inversely associated with CR (odds ratio [OR] 0.955 per 100 mL, p:0.029), persisting after adjustment for sex, MIPI, TP53, and histology (OR 0.914, 0.854-0.979, p:0.010). Adding TMTV to clinicopathologic risk factors did not improve discrimination for CR (AUC 0.829 vs 0.747, p:0.294). In Cox regression models adjusted for age, MIPI, TP53, histology for both outcomes, and additional ECOG GELF for PFS, continuous TMTV (HR 1.035, 95% CI 1.01-1.06, p:0.011) and continuous TLG (HR 1.01, 1.00-1.01, p:0.024) were independently associated with PFS; neither was associated with OS (TMTV p:0.491; TLG p:0.574). The composite MIPI/TMTV median was associated with CR univariately (high TMTV plus intermediate/high MIPI vs low MIPI, OR 0.15, 0.03-0.80, p:0.026; adjusted OR 0.22, p:0.103). OS differed across the 3 groups (log-rank p:0.028). Univariate HRs of death were 3.36 (p:0.027) for high TMTV + Intermediate/High MIPI and 3.74 (p:0.017) for low TMTV + Intermediate/High MIPI, with adjusted HRs of 3.66 (p:0.078) and 6.48 (p:0.018) when compared against low MIPI.

Conclusion
High baseline TMTV and TLG independently associate with outcomes including first-line CR and PFS in MCL but did not meaningfully improve risk stratification when added to established clinicopathologic risk factors. A composite of MIPI and TMTV was associated with CR and OS, but hazard ratios were similar for high- and low-TMTV patients within the intermediate/high MIPI stratum suggesting the difference is driven by MIPI. Additional studies examining TMTV and TLG and outcomes after BTK inhibitors and cellular therapy would be useful in understanding the role functional volumetric assessments in MCL.

Mohammad Oussama Ali, MD: No relevant conflicts of interest to declare.